During 2020 and 2021, some people on biologic disease-modifying antirheumatic drugs (bDMARDs) for arthritis and other musculoskeletal conditions have reported long delays in receiving their scripts and access to their medication.

The Consumer Advisory Committees of Musculoskeletal Australia and Arthritis Australia want to know if you have also experienced similar delays and what the impact has been for you (or your child, if they are on a biologic DMARD). If broad problems are evident, Musculoskeletal Australia and Arthritis Australia will work together with other relevant groups to try to address the issues causing these delays.

If you are on a biologic DMARD for your arthritis and other musculoskeletal condition/s, we would be very grateful if you could respond to a short, online survey. It will take no more than 5 minutes of your time. The survey closes on Monday 14 March and the results will be made available in April 2022.



Keep Reading